JSPR - Jasper Therapeutics to Present at the Cantor Fitzgerald 2023 Global Healthcare Conference | Benzinga
REDWOOD CITY, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced that it will participate at the Cantor Fitzgerald 2023 Global Healthcare Conference, to be held from September 26-28, 2023 in New York City.
Ronald Martell, Jasper's Chief Executive Officer, is scheduled to present on Wednesday, September 27th at 3:00PM ET. A live webcast of the presentation will be available here and on the Company's Investor Events webpage.
About Jasper Therapeutics
Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA) and severe combined immunodeficiency (SCID). To date, briquilimab has demonstrated efficacy and safety profile in over 130 dosed subjects and healthy volunteers, with clinical outcomes as a conditioning agent in SCID, acute myeloid leukemia (AML), MDS, FA, and SCD. In addition, briquilimab is being advanced as a transformational non-genotoxic conditioning agent for gene therapy. For more ...